Monthly Newsletter

AMSBIO has interviewed two extraordinary women in the 3D Cell Culture and Organoid field; Dr Hynda Kleinman, one of the co-inventors of Matrigel, and Dr Meritxell Huch, a director at the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) to mark International Women’s Day on the 8th March, and World Organoid Research Day on 22nd March 2023.

Topics covered in this informative interview include: how they got into 3D organoid culture research; their experiences in the field and how the field has changed; challenges they have overcome as female researchers; their current research interests; and advice for up and coming female scientists.

Asked ‘If there’s one thing you would like other scientists to understand about your area of research’ - Dr Kleinman said “Organoids have huge potential for studying genes, factors, or drugs for diagnostics and therapeutics as well as for tissue engineering / repair / regeneration either as delivery systems or tissue replacement. Try anything!”

When asked about her current research in the organoid space, Dr Huch answered “What I love is looking through the microscope and seeing these amazing multicellular structures form and develop. I still find it fascinating that we can take a piece of tissue and expand it for months in a dish while still retaining its identity. This really broke the long-held belief that primary epithelial cells could not be expanded”.

Organoids are organ-like structures formed by 3D cell culture and differentiation of stem cells or organ progenitors. Wide research interest in organoids comes from the fact that they are capable of replicating aspects of organ function in vitro. AMSBIO offers a suite of products to assist the increasing number of scientists adopting these structures for use in creating models for tissue morphogenesis and organogenesis; tumor, disease and infection research: drug testing; toxicity screening; personalized and regenerative medicine.

Read the interview in full

About AMS Biotechnology

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.

Recent news from AMSBIO